Citius Oncology Stock Forecast

CTOR's stock price has decreased by -93.98% in the past year and price targets may not have had time to catch up.

Stock Price Forecast

The 2 analysts with 12-month price forecasts for Citius Oncology stock have an average target of 4.50, with a low estimate of 3.00 and a high estimate of 6.00. The average target predicts an increase of 576.69% from the current stock price of 0.67.

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$3.00	$4.50	$6.00	$6.00
Change	+351.13%	+576.69%	+802.26%	+802.26%

* Price targets were last updated on Nov 27, 2024.

Analyst Ratings

The average analyst rating for Citius Oncology stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jan '25	Feb '25	Mar '25
Strong Buy	2	2	2
Buy	0	0	0
Hold	0	0	0
Sell	0	0	0
Strong Sell	0	0	0
Total	2	2	2

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Michael Okunewitch Maxim Group	Maxim Group	Strong Buy Initiates $3	Strong Buy	Initiates	$3	+351.13%	Nov 27, 2024
Jason Kolbert EF Hutton	EF Hutton	Strong Buy Maintains $6	Strong Buy	Maintains	$6	+802.26%	Aug 13, 2024

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

Revenue Next Year

n/a

EPS This Year

n/a

EPS Next Year

n/a

No financial forecasts available for this stock

Revenue Forecast

No data available

Revenue Growth

No data available

EPS Forecast

No data available

EPS Growth

No data available

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.